BP_04 - 2001

Monographs

Formulated Preparations:Specific Monographs

46-2

FORMULATED PREPARATIONS:SPECIFIC MONOGRAPHS

Acebutolol CapsulesDefinition Acebutolol Capsules contain Acebutolol Hydrochloride.

The capsules comply with the requirements stated under Capsules and with the following requirements.

Content of acebutolol, C18H28N2O4 95.0 to 105.0% of the stated amount.

Identification The infrared absorption spectrum of a 0.7% w/w dispersion of the contents of thecapsules in potassium bromide, Appendix II A, is concordant with the reference spectrum of acebutololhydrochloride (RS 380).

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using aprecoated silica gel F254 plate (Merck silica gel 60 F254 plates are suitable) and a mixture of 20volumes of glacial acetic acid, 20 volumes of dimethylformamide and 60 volumes of chloroform as themobile phase. Apply separately to the plate 10 l of each of the following solutions. For solution (1)add to a quantity of the contents of the capsules containing the equivalent of 0.4 g of acebutolol20 ml of a mixture of equal volumes of chloroform and methanol, shake for 2 minutes, centrifuge anduse the supernatant liquid. For solution (2), dilute 3 volumes of solution (1) to 100 volumes with amixture of equal volumes of chloroform and methanol and further dilute 1 volume of this solution to 10volumes with the same mixture of solvents. For solution (3), dilute 1 volume of solution (1) to 100volumes with a mixture of equal volumes of chloroform and methanol and further dilute 1 volume ofthis solution to 10 volumes with the same mixture of solvents. After removal of the plate, allow it todry in air and examine under ultraviolet light (254 nm). Any secondary spot in the chromatogramobtained with solution (1) is not more intense than the spot in the chromatogram obtained withsolution (2) (0.3%) and not more than two such spots are more intense than the spot in the chrom-atogram obtained with solution (3) (0.1%). Disregard any spot remaining on the line of application.

Assay To a quantity of the mixed contents of 20 capsules containing the equivalent of 0.15 g ofacebutolol add 150 ml of water, shake for 10 minutes, add sufficient water to produce 250 ml,centrifuge and dilute 10 ml of the supernatant liquid to 100 ml with water. To 10 ml of this solutionadd 10 ml of 0.1M hydrochloric acid and sufficient water to produce 100 ml. Measure the absorbance ofthis solution, Appendix II B, at the maximum at 233 nm and calculate the content of C18H28N2O4 inthe capsules taking 580 as the value of A(1%, 1 cm) at the maximum at 233 nm.

Storage Acebutolol Capsules should be kept at a temperature not exceeding 25 and protected fromlight.

Labelling The quantity of the active ingredient is stated in terms of the equivalent amount ofacebutolol.

46-3

Acebutolol TabletsDefinition Acebutolol Tablets contain Acebutolol Hydrochloride.

The tablets comply with the requirements stated under Tablets and with the following requirements.

Content of acebutolol, C18H28N2O4 95.0 to 105.0% of the stated amount.

Identification The infrared absorption spectrum of a 0.7% w/w dispersion of the powdered tablets inpotassium bromide, Appendix II A, is concordant with the reference spectrum of acebutolol hydro-chloride (RS 380).

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using aprecoated silica gel F254 plate (Merck silica gel 60 F254 plates are suitable) and a mixture of 20volumes of glacial acetic acid, 20 volumes of dimethylformamide and 60 volumes of chloroform as themobile phase. Apply separately to the plate 10 l of each of the following solutions. For solution (1)add to a quantity of the powdered tablets containing the equivalent of 0.4 g of acebutolol 20 ml of amixture of equal volumes of chloroform and methanol, shake for 2 minutes, centrifuge and use thesupernatant liquid. For solution (2), dilute 3 volumes of solution (1) to 100 volumes with a mixtureof equal volumes of chloroform and methanol and further dilute 1 volume of this solution to 10volumes with the same mixture of solvents. For solution (3), dilute 1 volume of solution (1) to 100volumes with a mixture of equal volumes of chloroform and methanol and further dilute 1 volume ofthis solution to 10 volumes with the same mixture of solvents. After removal of the plate, allow it todry in air and examine under ultraviolet light (254 nm). Any secondary spot in the chromatogramobtained with solution (1) is not more intense than the spot in the chromatogram obtained withsolution (2) (0.3%) and not more than two such spots are more intense than the spot in the chrom-atogram obtained with solution (3) (0.1%). Disregard any spot remaining on the line of application.

Assay Shake a number of whole tablets containing the equivalent of 4 g of acebutolol with 250 ml ofwater until completely disintegrated, add sufficient water to produce 1000 ml, filter and dilute 10 mlof the filtrate to 250 ml with water. To 10 ml of this solution add 20 ml of 0.1M hydrochloric acid andsufficient water to produce 200 ml. Measure the absorbance of this solution, Appendix II B, at themaximum at 233 nm and calculate the content of C18H28N2O4 in the tablets taking 580 as the valueof A(1%, 1 cm) at the maximum at 233 nm.

Storage Acebutolol Tablets should be kept at a temperature not exceeding 25.

Labelling The quantity of the active ingredient is stated in terms of the equivalent amount ofacebutolol.

46-4

Acenocoumarol Tablets / Nicoumalone TabletsFor the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Acenocoumarol Tablets contain Acenocoumarol.


Content of acenocoumarol, C19H15NO6 92.5 to 107.5% of the stated amount.

IdentificationA. Heat a quantity of the powdered tablets containing 50 mg of Acenocoumarol with 30 ml of acetoneunder a reflux condenser for 5 minutes, filter and wash the residue with two 10-ml quantities ofacetone. Evaporate the combined filtrate and washings to 5 ml, add water dropwise until the solutionbecomes turbid, heat on a water bath until the solution is clear and allow to stand. Filter, wash thecrystals with a mixture of equal volumes of acetone and water and dry at 100 at a pressure of 2 kPafor 30 minutes. The infrared absorption spectrum of the residue, Appendix II A, is concordant with thereference spectrum of acenocoumarol (RS 001).

B. The light absorption, Appendix II B, of the final solution obtained in the Assay exhibits maxima at283 nm and 306 nm.

C. Heat 25 mg of the residue obtained in test A with 2.5 ml of glacial acetic acid, 0.5 ml of hydro-chloric acid and 0.2 g of zinc powder on a water bath for 5 minutes, cool and filter. To the filtrate add0.05 ml of sodium nitrite solution and add the mixture to 10 ml of a 1% w/v solution of 2-naphtholcontaining 3 ml of 5M sodium hydroxide. A bright red precipitate is produced.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a mixture of 20 volumes of glacial acetic acid, 50 volumes ofchloroform and 50 volumes of cyclohexane as the mobile phase. Apply separately to the plate 20 l ofeach of the following solutions. For solution (1) shake a quantity of the powdered tablets containing20 mg of Acenocoumarol with 5 ml of acetone, centrifuge and use the supernatant liquid. For solution(2) dilute 1 volume of solution (1) to 200 volumes with acetone. After removal of the plate, allow it todry in air and immediately examine under ultraviolet light (254 nm). Any secondary spot in the chrom-atogram obtained with solution (1) is not more intense than the spot in the chromatogram obtainedwith solution (2) (0.5%).

Uniformity of content Tablets containing 4 mg or less of Acenocoumarol comply with the require-ments stated under Tablets using the following method of analysis. Finely crush one tablet, add30 ml of methanol, stir the mixture for 30 minutes and filter through sintered glass, washing theresidue with three 15-ml quantities of methanol. To the combined filtrate and washings add 10 ml of1M hydrochloric acid and sufficient methanol to produce 100 ml. If necessary dilute further with asolvent prepared by diluting 1 volume of 1M hydrochloric acid to 10 volumes with methanol to producea solution containing about 0.001% w/v of Acenocoumarol. Measure the absorbance of the resultingsolution at the maximum at 306 nm, Appendix II B. Calculate the content of C19H15NO6 taking 521as the value of A(1%, 1 cm) at the maximum at 306 nm.

Assay Weigh and powder 20 tablets. To a quantity of the powder containing 1 mg ofAcenocoumarol add 30 ml of methanol, stir the mixture for 30 minutes and filter through sinteredglass, washing the residue with three 15-ml quantities of methanol. To the combined filtrate andwashings add 10 ml of 1M hydrochloric acid and sufficient methanol to produce 100 ml and measurethe absorbance of the resulting solution at the maximum at 306 nm, Appendix II B. Calculate thecontent of C19H15NO6 taking 521 as the value of A(1%, 1 cm) at the maximum at 306 nm.

Labelling The label states Acenocoumarol Tablets and Nicoumalone Tablets.

46-5

Acetazolamide TabletsDefinition Acetazolamide Tablets contain Acetazolamide.


Content of acetazolamide, C4H6N4O3S2 95.0 to 105.0% of the stated amount.

IdentificationA. Shake a quantity of the powdered tablets containing 0.5 g of Acetazolamide with 2 ml of 1Msodium hydroxide and filter. Neutralise the filtrate with glacial acetic acid, filter and dry the resultingprecipitate at 105. The infrared absorption spectrum of the residue, Appendix II A, is concordant withthe reference spectrum of acetazolamide (RS 002).

B. Triturate a quantity of the powdered tablets containing 0.5 g of Acetazolamide with a mixture of5 ml of water and 1 ml of 1M sodium hydroxide, transfer to a test tube, add 0.2 g of zinc powder and0.5 ml of hydrochloric acid and immediately place a piece of lead acetate paper over the mouth of thetube. The paper exhibits a brownish black colour.

C. To a quantity of the powdered tablets containing 25 mg of Acetazolamide add 5 ml of water,0.15 ml of 1M sodium hydroxide and 0.1 ml of weak copper sulphate solution. A greenish blue colour orprecipitate is produced.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a freshly prepared mixture of 50 volumes of propan-2-ol, 30volumes of ethyl acetate and 20 volumes of 13.5M ammonia as the mobile phase. Use the tank withoutlining the walls and allow to saturate for 1 hour before development. Apply separately to the plate20 l of each of the following solutions. For solution (1) shake a quantity of the powdered tabletscontaining 50 mg of Acetazolamide for 20 minutes with 10 ml of a mixture of equal volumes ofethanol (96%) and ethyl acetate and filter. For solution (2) dilute 1 volume of solution (1) to 100volumes with the same solvent mixture. After removal of the plate, allow it to dry in air and examineunder ultraviolet light (254 nm). Any secondary spot in the chromatogram obtained with solution (1) isnot more intense than the spot in the chromatogram obtained with solution (2) (1%).

Assay Weigh and powder 20 tablets. To a quantity of the powder containing 0.4 g of Acetazolamideadd 90 ml of dimethylformamide and carry out Method II for non-aqueous titration, Appendix VIII A,using 0.1M tetrabutylammonium hydroxide VS as titrant and determining the end point potentio-metrically. Each ml of 0.1M tetrabutylammonium hydroxide VS is equivalent to 22.22 mg ofC4H6N4O3S2.

46-6

Acetylcysteine InjectionDefinition Acetylcysteine Injection is a sterile solution in Water for Injections of acetylcysteinesodium, prepared by the interaction of Acetylcysteine with Sodium Hydroxide.

The injection complies with the requirements stated under Parenteral Preparations and with the followingrequirements.

Content of acetylcysteine, C5H9NO3S 95.0 to 105.0% of the stated amount.

Identification To a volume containing the equivalent of 0.8 g of Acetylcysteine add 3M hydrochloricacid until the pH of the solution is 2. Add, while stirring continuously, two 200-mg portions of finelypowdered sodium chloride followed, if necessary, by further 25-mg portions of sodium chloride until aprecipitate begins to appear. Allow to stand for 15 minutes, filter and dry the residue at 70 at apressure not exceeding 0.7 kPa for 2 hours. The infrared absorption spectrum of the residue, AppendixII A, is concordant with the reference spectrum of acetylcysteine (RS 003). Examine as discs preparedusing potassium bromide.

Acidity or alkalinity pH, 6.5 to 7.5, Appendix V L.

Specific optical rotation +21 to +27, Appendix V F. To a volume containing the equivalent of1.25 g of Acetylcysteine add 1 ml of a 0.1% w/v solution of disodium edetate and sufficient mixedphosphate buffer pH 7.0 to produce 25 ml.

Related substances Carry out the method for liquid chromatography, Appendix III D, using thefollowing solutions. With the exception of solution (3), the solutions should be prepared immediatelybefore use. For solution (1) dilute the injection with the mobile phase to produce a solution contain-ing the equivalent of 0.2% w/v of Acetylcysteine. Solution (2) is a 0.2% w/v solution of N-acetyl-L-cysteine in the mobile phase. Prepare solution (3) in the same manner as solution (2) but store atroom temperature for at least 2 hours before use. For solution (4) dissolve 20 mg of L-cysteine and20 mg of L-cystine in 10 ml of 1M hydrochloric acid, add 40 mg of N-acetyl-L-cysteine and immediatelydilute to 100 ml with the mobile phase. Dilute 10 ml of the resulting solution to 200 ml with themobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(25 cm 5 mm) packed with stationary phase C (5 m) (Lichrosorb RP18 is suitable), (b) as themobile phase with a flow rate of 1 ml per minute a mixture of 10 volumes of methanol and 90volumes of a 0.5% w/v solution of ammonium sulphate containing 0.02M sodium pentanesulphonate, thesolution being adjusted to pH 2 using 2M hydrochloric acid, and (c) a detection wavelength of 205 nm.

Inject 20 l of solution (4). The chromatogram obtained shows three peaks with retention times ofabout 3.6 minutes (cystine), about 4 minutes (cysteine) and about 6 minutes (acetylcysteine). Adjustthe sensitivity so that the height of the peak due to cysteine is about 20% of full-scale deflection. Thetest is not valid unless, in the chromatogram obtained with solution (4), the height of the troughseparating the peaks due to cysteine and cystine is less than one quarter of the height of the peak dueto cysteine. Inject 20 l of solutions (2) and (3) and allow the chromatography to continue for threetimes the retention time of acetylcysteine. In the chromatogram obtained with solution (3) a peak dueto N,N-diacetylcystine appears which has a retention time of about 13 minutes. The area of thispeak is greater than the area of any corresponding peak in the chromatogram obtained with solution(2).

In the chromatogram obtained with solution (1) the area of any peak corresponding to N,N-diacetylcystine is not greater than the area of the peak due to acetylcysteine in the chromatogramobtained with solution (4) (1%), the area of any peak due to cysteine or cystine is not greater than thecorresponding peak in the chromatogram obtained with solution (4) (0.5%) and the sum of the areasof any other secondary peaks is not greater than the area of the peak due to acetylcysteine in thechromatogram obtained with solution (4) (1%).

Hydrogen sulphide Place a quantity of the injection containing the equivalent of 0.4 g ofAcetylcysteine in a round-bottomed, three-necked flask containing 40 ml of water. The flask is fittedwith a gas inlet tube which reaches nearly to the bottom of the flask, a dropping funnel containinghydrochloric acid and an outlet tube leading to a 100-ml graduated flask containing a mixture of 1 mlof 5M sodium hydroxide and 50 ml of water. Pass through the flask a steady current of nitrogen andadd 10 ml of hydrochloric acid from the dropping funnel. Maintain the current of nitrogen for 30minutes and then disconnect the absorption flask. Add to the flask 10 ml of a solution prepared bydissolving 0.1 g of N,N-dimethyl-p-phenylenediamine dihydrochloride in a mixture of 45 ml of hydro-chloric acid and 55 ml of water decolorised with activated charcoal before use, if necessary, and 5 ml ofa 5% w/v solution of iron(III) chloride hexahydrate in 1M hydrochloric acid and allow to stand for 20minutes protected from light. Add sufficient water to produce 100 ml and measure the absorbance ofthe solution, Appendix II B, at 665 nm using a 4-cm pathlength and using in the reference cell asolution prepared in the same manner but without the injection being examined.

Prepare a 0.4% w/v solution of sodium sulphide. Standardise this solution in the following manner.To 25 ml of 0.005M iodine VS add 8 ml of hydrochloric acid and 25 ml of the sodium sulphide

46-7

solution. Titrate with 0.1M sodium thiosulphate solution VS using starch solution, added towards the endpoint, as indicator. Repeat the operation without the sodium sulphide solution. The concentration ofthe sodium sulphide solution expressed in parts per million of hydrogen sulphide is the differencebetween the titrations multiplied by 68.16. Prepare a solution containing the equivalent of 20 ppm ofhydrogen sulphide by appropriate dilution of the sodium sulphide solution with water.

Repeat the procedure carried out on the injection using 2 ml of the 20 ppm hydrogen sulphidesolution in place of the injection being examined. The absorbance of the solution obtained from theinjection is not greater than the absorbance of the solution obtained from the standard (100 ppmwith reference to the content of acetylcysteine).

Pyrogens Complies with the test for pyrogens, Appendix XIV D. Use per kg of the rabbits weight avolume containing the equivalent of 0.3 g of Acetylcysteine.

Assay Add 20 ml of glacial acetic acid to a volume containing the equivalent of 0.4 g of Acetylcysteineand titrate with 0.05M iodine VS until a permanent pale yellow colour is obtained. Each ml of 0.05Miodine VS is equivalent to 16.23 mg of C5H9NO3S.

Storage Acetylcysteine Injection should be protected from light.

Labelling The strength is stated in terms of an equivalent percentage w/v of Acetylcysteine.

46-8

Aciclovir CreamDefinition Aciclovir Cream contains Aciclovir in a suitable basis.

The cream complies with the requirements stated under Topical Semi-solid Preparations and with the follow-ing requirements.

Content of aciclovir, C8H11N5O3 95.0 to 105.0% of the stated amount.

IdentificationA. The light absorption, Appendix II B, in the range 230 to 350 nm of the solution prepared in theAssay exhibits a maximum at 255 nm and a broad shoulder at about 274 nm.

B. In the test for Guanine, the principal spot in the chromatogram obtained with solution (2) issimilar in position and intensity to that in the chromatogram obtained with solution (3).

Guanine Carry out the method for thin-layer chromatography, Appendix III A, using cellulose F254 asthe coating substance (Merck cellulose F plates are suitable). Apply separately to the plate 10 l ofeach of the following solutions. For solution (1) transfer a quantity of the well-mixed cream contain-ing 30 mg of Aciclovir into a 10-ml graduated, stoppered centrifuge tube, add 3 ml of 0.1M sodiumhydroxide and shake to disperse the cream. Add 5 ml of a mixture of 1 volume of chloroform and 2volumes of propan-1-ol, shake well, centrifuge and dilute the upper aqueous layer to 5 ml with 0.1Msodium hydroxide, mix, centrifuge and use the upper aqueous layer. For solution (2) dilute 1 volumeof solution (1) to 10 volumes with 0.1M sodium hydroxide. For solution (3) dissolve 6.0 mg of aciclovirBPCRS in 10 ml of 0.1M sodium hydroxide. For solution (4) dissolve 6.0 mg of guanine in 100 ml of0.1M sodium hydroxide. Use ethyl acetate for the first mobile phase but allow the solvent front toascend to the top of the plate. After removal of the plate, dry it in a current of air and repeat thedevelopment in the same direction using a mixture of 10 volumes of propan-1-ol, 30 volumes of13.5M ammonia and 60 volumes of a 5% w/v solution of ammonium sulphate as the mobile phase andallowing the solvent front to ascend 8 cm above the line of application. After removal of the plate,allow it to dry in air and examine under ultraviolet light (254 nm). Any secondary spot corresponding toguanine in the chromatogram obtained with solution (1) is not more intense than the spot in thechromatogram obtained with solution (4) (1.0%). Disregard any spot that appears just below thesolvent front.

Assay Shake a quantity of the well-mixed cream containing about 7.5 mg of Aciclovir with 50 ml of0.5M sulphuric acid. Shake well with 50 ml of ethyl acetate, allow to separate and collect the clear loweraqueous layer. Wash the organic layer with 20 ml of 0.5M sulphuric acid and dilute the combinedwashings and the aqueous layer to 100 ml with 0.5M sulphuric acid. Mix well and filter (WhatmanGF/F is suitable). Discard the first few ml of filtrate and to 10 ml of the filtrate add sufficient water toproduce 50 ml. Measure the absorbance of the resulting solution at the maximum at 255 nm,Appendix II B. Calculate the content of C8H11N5O3 taking 562 as the value of A(1%, 1 cm) at themaximum at 255 nm.

Storage Aciclovir Cream should be stored at a temperature not exceeding 25.

46-9

Aciclovir Eye OintmentDefinition Aciclovir Eye Ointment is a sterile preparation containing Aciclovir in a suitable basis.

The eye ointment complies with the requirements stated under Eye Preparations and with the followingrequirements.




Guanine Complies with the test described under Aciclovir Intravenous Infusion but preparingsolution (1) in the following manner. Disperse a quantity of the eye ointment containing 30 mg ofAciclovir in 100 ml of hexane, extract with 5 ml of 0.1M sodium hydroxide, allow to separate and retainthe lower aqueous layer.

Assay Disperse a quantity of the eye ointment containing 10 mg of Aciclovir in 60 ml of hexane.Extract with three 30-ml quantities of 0.1M of sodium hydroxide, add sufficient 0.1M sodium hydroxideto produce 100 ml and filter. To 15 ml of this solution add 5 ml of 2M hydrochloric acid and sufficientwater to produce 100 ml. Measure the absorbance of the resulting solution at the maximum at255 nm, Appendix II B. Calculate the content of C8H11N5O3 taking 560 as the value of A(1%, 1 cm)at the maximum at 255 nm.

46-10

Aciclovir Intravenous InfusionDefinition Aciclovir Intravenous Infusion is a sterile solution of aciclovir sodium in Water for Injec-tions. It is prepared by dissolving Aciclovir Sodium for Intravenous Infusion in the requisite amountof Water for Injections before use.

The intravenous infusion complies with the requirements stated under Parenteral Preparations and with thefollowing requirements.

Bacterial endotoxins Carry out the test for bacterial endotoxins, Appendix XIV C. The endotoxinlimit concentration of the intravenous infusion, diluted, if necessary, with water BET to give a solu-tion containing the equivalent of 25 mg of Aciclovir per ml is 4.37 IU per ml. Carry out the test usingthe maximum valid dilution of the above defined solution calculated from the declared sensitivity ofthe lysate used in the test.

Storage Aciclovir Intravenous Infusion should be used within the period recommended by themanufacturer when prepared and stored strictly in accordance with the manufacturers instructions.

Labelling The strength is stated as the equivalent amount of Aciclovir in a suitable dose-volume.

ACICLOVIR SODIUM FOR INTRAVENOUS INFUSION

Definition Aciclovir Sodium for Intravenous Infusion is a sterile material prepared from Aciclovirwith the aid of a suitable alkali. It may contain excipients. It is supplied in a sealed container.

The contents of the sealed container comply with the requirements for Powders for Injections stated underParenteral Preparations and with the following requirements.




C. Yield reaction A characteristic of sodium salts, Appendix VI.

Alkalinity Dissolve the contents of a sealed container in sufficient water for injections to produce asolution containing the equivalent of 2.5% w/v of Aciclovir (solution A). The pH of solution A is10.7 to 11.7, Appendix V L.

Clarity and colour of solution Solution A is not more opalescent than reference suspension II,Appendix IV A, and not more intensely coloured than reference solution Y6, Appendix IV B,Method II.

Guanine Carry out the method for thin-layer chromatography, Appendix III A, using cellulose F254 asthe coating substance (Merck cellulose F plates are suitable) and a mixture of 10 volumes of propan-1-ol, 30 volumes of 13.5M ammonia and 60 volumes of a 5% w/v solution of ammonium sulphate as themobile phase but allowing the solvent front to ascend 12 cm above the line of application. Applyseparately to the plate 10 l of each of the following solutions. For solution (1) dissolve the contentsof a sealed container in sufficient 0.1M sodium hydroxide to produce a solution containing theequivalent of 0.5% w/v of Aciclovir. For solution (2) dilute 1 volume of solution (1) to 10 volumeswith 0.1M sodium hydroxide. For solution (3) dissolve 5 mg of aciclovir BPCRS in 10 ml of 0.1Msodium hydroxide. For solution (4) dissolve 5 mg of guanine in 100 ml of 0.1M sodium hydroxide. Afterremoval of the plate, allow it to dry in air and examine under ultraviolet light (254 nm). Any secondaryspot corresponding to guanine in the chromatogram obtained with solution (1) is not more intensethan the spot in the chromatogram obtained with solution (4) (1%). Disregard any spot that appearsjust below the solvent front.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a mixture of 2 volumes of 13.5M ammonia, 20 volumes ofmethanol and 80 volumes of dichloromethane as the mobile phase but allowing the solvent front toascend 10 cm above the line of application. Apply separately to the plate 2 l of each of the followingfreshly prepared solutions. For solution (1) dissolve the contents of a sealed container in sufficientdimethyl sulphoxide to produce a solution containing the equivalent of 2.5% w/v of Aciclovir. Forsolution (2) dilute 1 volume of solution (1) to 200 volumes with dimethyl sulphoxide. After removal ofthe plate, allow it to dry in air and examine under ultraviolet light (254 nm). In the chromatogramobtained with solution (1) any secondary spot with an Rf value greater than that of the principal spot isnot more intense than the spot in the chromatogram obtained with solution (2) (0.5%).

Assay Determine the weight of the contents of 10 containers as described in the test for Uniformityof weight under Parenteral Preparations, Powders for Injections.

Dissolve the total contents of 10 containers in sufficient 0.1M hydrochloric acid to produce 500 ml.

46-11

Dilute 3 ml of the resulting solution to 100 ml with 0.1M hydrochloric acid and dilute 5 ml of theresulting solution with the same solvent to produce a solution containing the equivalent of 0.0015%w/v of Aciclovir. Measure the absorbance at the maximum at 255 nm, Appendix II B. Calculate thecontent of C8H11N5O3 taking 560 as the value of A(1%, 1 cm) at the maximum at 255 nm.

Storage The sealed container should be stored at a temperature not exceeding 25.

Labelling The label of the sealed container states the quantity of aciclovir sodium in terms of theequivalent amount of Aciclovir.

46-12

Aciclovir Oral SuspensionDefinition Aciclovir Oral Suspension is a suspension of Aciclovir in a suitable flavoured vehicle.

The oral suspension complies with the requirements stated under Oral Liquids and with the following require-ments.


IdentificationA. The light absorption, Appendix II B, in the range 230 to 250 nm of the solution prepared in theAssay before the final dilution exhibits a maximum at 255 nm and a broad shoulder at about 274 nm.

B. In the test for Guanine, the principal spot in the chromatogram obtained with solution (2) issimilar in position and intensity to that in the chromatogram obtained with solution (3). If the Rfvalues of the principal spots in the chromatograms obtained with solutions (2) and (3) are different,the oral suspension complies if the chromatogram obtained with solution (5) shows a single, compactspot.

Acidity pH, 4.0 to 7.0, Appendix V L.

Guanine Carry out the test described under Aciclovir Intravenous Infusion but applying 5 l of eachof the following solutions. For solution (1) add 20 ml of 0.1M sodium hydroxide to a quantity of theoral suspension containing 0.6 g of Aciclovir, shake to disperse and add sufficient absolute ethanol toproduce 100 ml. Mix well and allow any suspended material to settle before application to the plate.For solution (2) dilute 1 volume of solution (1) to 10 volumes with a mixture of 35 volumes of 0.1Msodium hydroxide and 65 volumes of absolute ethanol. For solution (3) dissolve 6 mg of aciclovirBPCRS in 10 ml of a mixture of 35 volumes of 0.1M sodium hydroxide and 65 volumes of absoluteethanol. For solution (4) dissolve 6 mg of guanine in 100 ml of a mixture of 35 volumes of 0.1Msodium hydroxide and 65 volumes of absolute ethanol (1%). Solution (5) contains equal volumes ofsolutions (2) and (3).

Assay To a weighed quantity containing 0.4 g of Aciclovir add 400 ml of water and 25 ml of 1Msulphuric acid, shake well, disperse with the aid of ultrasound for 10 minutes and add sufficient waterto produce 500 ml. Filter the resulting solution, discard the first few ml of filtrate and dilute 5 ml ofthe filtrate to 200 ml with 0.05M sulphuric acid. Add 10 ml of the resulting solution to 5 ml of a0.01% w/v solution of cetrimide in 0.05M sulphuric acid, add sufficient 0.05M sulphuric acid to produce100 ml and measure the fluorescence, Appendix II E, using an excitation wavelength of 308 nm and anemission wavelength of 415 nm. Set the instrument to zero using a 0.0005% w/v solution of cetrimidein 0.05M sulphuric acid. Calculate the content of C8H11N5O3 in the oral suspension from the fluores-cence obtained by carrying out the operation at the same time using a mixture prepared by adding10 ml of a 0.002% w/v solution of aciclovir BPCRS in 0.05M sulphuric acid and beginning at the wordsto 5 ml of a 0.01% w/v solution of cetrimide .... Determine the weight per ml of the oral suspension,Appendix V G, and calculate the content of C8H11N5O3, weight in volume, using the declaredcontent of C8H11N5O3 in aciclovir BPCRS.

Storage Aciclovir Oral Suspension should be stored at a temperature not exceeding 25.

46-13

Aciclovir TabletsDefinition Aciclovir Tablets contain Aciclovir.

With the exception of the requirements for shape, the tablets comply with the requirements stated under Tabletsand with the following requirements.




Guanine Comply with the test described under Aciclovir Intravenous Infusion but preparing solu-tion (1) in the following manner. Shake a quantity of the powdered tablets containing 0.25 g ofAciclovir with 25 ml of 0.1M sodium hydroxide for 10 minutes. Add a sufficient quantity of 0.1Msodium hydroxide to produce 50 ml, allow to stand and allow any undissolved material to settle beforeapplication to the plate.

Dissolution Comply with the dissolution test for tablets and capsules, Appendix XII D, using ApparatusII. Use as the medium 900 ml of 0.1M hydrochloric acid and rotate the paddle at 50 revolutions perminute. Withdraw a sample of 25 ml of the medium and filter. Measure the absorbance of the filteredsolution, diluted if necessary with 0.1M hydrochloric acid, at the maximum at 255 nm, Appendix II B.Calculate the total content of aciclovir, C8H11N5O3, in the medium taking 560 as the value of A(1%,1 cm) at the maximum at 255 nm.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a mixture of 2 volumes of 13.5M ammonia, 20 volumes ofmethanol and 80 volumes of dichloromethane as the mobile phase but allowing the solvent front toascend 10 cm above the line of application. Apply separately to the plate 2 l of each of the followingfreshly prepared solutions. For solution (1) shake a quantity of the powdered tablets containing0.25 g of Aciclovir with 10 ml of dimethyl sulphoxide for 15 minutes and filter. For solution (2) dilute0.7 volumes of solution (1) to 100 volumes with dimethyl sulphoxide. After removal of the plate, allowit to dry in air and examine under ultraviolet light (254 nm). In the chromatogram obtained withsolution (1) any secondary spot with an Rf value greater than that of the principal spot is not moreintense than the spot in the chromatogram obtained with solution (2) (0.7%).

Assay Weigh and finely powder 20 tablets. To a quantity of the powdered tablets containing 0.1 g ofAciclovir add 60 ml of 0.1M sodium hydroxide and disperse with the aid of ultrasound for 15 minutes.Add a sufficient quantity of 0.1M sodium hydroxide to produce 100 ml, mix well and filter. To 15 mlof the filtrate add 50 ml of water and 5.8 ml of 2M hydrochloric acid and sufficient water to produce100 ml. To 5 ml of the solution add sufficient 0.1M hydrochloric acid to produce 50 ml and mix well.Measure the absorbance of the resulting solution at the maximum at 255 nm, Appendix II B, using0.1M hydrochloric acid in the reference cell. Calculate the content of C8H11N5O3 taking 560 as thevalue of A(1%, 1 cm) at the maximum at 255 nm.

Storage Aciclovir Tablets should be stored at a temperature not exceeding 25.

46-14

Dispersible Aciclovir TabletsDefinition Dispersible Aciclovir Tablets contain Aciclovir in a suitable dispersible basis.





Guanine Comply with the test described under Aciclovir Intravenous Infusion but preparingsolution (1) in the following manner. Shake a quantity of the powdered tablets containing 0.25 g ofAciclovir with 25 ml of 0.1M sodium hydroxide for 10 minutes. Add a sufficient quantity of 0.1Msodium hydroxide to produce 50 ml, allow to stand and allow any undissolved material to settle beforeapplication to the plate.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a mixture of 2 volumes of 13.5M ammonia, 20 volumes ofmethanol and 80 volumes of dichloromethane as the mobile phase but allowing the solvent front toascend 10 cm above the line of application. Apply separately to the plate 2 l of each of the followingfreshly prepared solutions. For solution (1) shake a quantity of the powdered tablets containing0.25 g of Aciclovir with 10 ml of dimethyl sulphoxide for 15 minutes and filter. For solution (2) dilute0.7 volumes of solution (1) to 100 volumes with dimethyl sulphoxide. After removal of the plate, allowit to dry in air and examine under ultraviolet light (254 nm). In the chromatogram obtained withsolution (1) any secondary spot with an Rf value greater than that of the principal spot is not moreintense than the spot in the chromatogram obtained with solution (2) (0.7%).

Assay Weigh and finely powder 20 tablets. To a quantity of the powdered tablets containing 0.1 g ofAciclovir add 60 ml of 0.1M sodium hydroxide and disperse with the aid of ultrasound for 15 minutes.Add sufficient 0.1M sodium hydroxide to produce 100 ml, mix well and filter. To 15 ml of the filtrateadd 50 ml of water, 5.8 ml of 2M hydrochloric acid and sufficient water to produce 100 ml. To 5 ml ofthe solution add sufficient 0.1M hydrochloric acid to produce 50 ml and mix well. Measure theabsorbance of the resulting solution at the maximum at 255 nm, Appendix II B, using 0.1M hydro-chloric acid in the reference cell. Calculate the content of C8H11N5O3 taking 560 as the value ofA(1%, 1 cm) at the maximum at 255 nm.

Storage Dispersible Aciclovir Tablets should be stored at a temperature not exceeding 25.

Labelling The label states that the tablets should be dispersed in water immediately before use.

46-15

Adrenaline Eye Drops / Epinephrine Eye DropsNeutral Adrenaline Eye DropsNeutral Epinephrine Eye Drops

For the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Adrenaline Eye Drops are a sterile solution of Adrenaline in Purified Water.

The eye drops comply with the requirements stated under Eye Preparations and with the following require-ments.

Content of adrenaline, C9H13NO3 95.0 to 110.0% of the stated amount.

IdentificationA. In the Assay, the retention time of the principal peak in the chromatogram obtained with solution(2) is the same as that of the principal peak in the chromatogram obtained with solution (1).

B. To 1 ml of a dilution of the eye drops containing 0.1% w/v of Adrenaline adjusted, if necessary, toa neutral or slightly acidic pH add, dropwise, a 0.25% w/v solution of iron(III) chloride hexahydrateuntil a green colour is produced. On the gradual addition of sodium hydrogen carbonate solution, thesolution changes first to blue and then to red.

C. To 1 ml of a dilution of the eye drops containing 0.1% w/v of Adrenaline add 2 ml of a 10% w/vsolution of disodium hydrogen orthophosphate and sufficient iodinated potassium iodide solution toproduce a brown colour. Remove excess iodine by adding 0.2M sodium thiosulphate dropwise. A redcolour is produced.

Acidity or alkalinity pH, 5.5 to 7.6, Appendix V L.

Noradrenaline Carry out the method for liquid chromatography, Appendix III D, using the followingsolutions. Solution (1) contains 0.0018% w/v of noradrenaline acid tartrate in the mobile phase. Forsolution (2) dilute the eye drops with the mobile phase to produce a solution containing 0.10% w/vof Adrenaline. Solution (3) contains 0.0018% w/v of noradrenaline acid tartrate and 0.0018% w/v ofadrenaline acid tartrate BPCRS in the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as themobile phase with a flow rate of 2 ml per minute a solution containing 4.0 g of tetramethylammoniumhydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodium edetate in a mixture of950 ml of water and 50 ml of methanol, the pH of the mixture being adjusted to 3.5 with 1M sodiumhydroxide, and (c) a detection wavelength of 205 nm.

The test is not valid unless the resolution factor between the two principal peaks in the chromato-gram obtained with solution (3) is at least 2.0.

In the chromatogram obtained with solution (2) the area of any peak corresponding to noradren-aline is not greater than the area of the principal peak in the chromatogram obtained with solution(1) (1%).

Assay Carry out the method for liquid chromatography, Appendix III D, using the following solutions.Solution (1) contains 0.2% w/v of adrenaline acid tartrate BPCRS in the mobile phase. For solution(2) dilute the eye drops with sufficient mobile phase to produce a solution containing 0.1% w/v ofAdrenaline. Solution (3) contains 0.2% w/v of adrenaline acid tartrate BPCRS and 0.2% w/v ofnoradrenaline acid tartrate in the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as themobile phase with a flow rate of 2 ml per minute, a solution prepared by adding 4.0 g of tetra-methylammonium hydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodiumedetate to a mixture of 950 ml of water and 50 ml of methanol, the pH of the mixture being adjusted to3.5 with 1M sodium hydroxide and (c) a detection wavelength of 205 nm.


Calculate the content of C9H13NO3 in the eye drops using the declared content of C9H13NO3 inadrenaline acid tartrate BPCRS.

Storage Adrenaline Eye Drops should be protected from light.

Labelling The label states Adrenaline Eye Drops and Epinephrine Eye Drops.

46-16

Adrenaline Injection /Epinephrine InjectionAdrenaline Tartrate InjectionEpinephrine Tartrate Injection


Definition Adrenaline Injection is a sterile, isotonic solution containing 0.18% w/v of AdrenalineAcid Tartrate in Water for Injections.


Content of adrenaline, C9H13NO3 0.09 to 0.11% w/v.

Characteristics A colourless solution.

IdentificationA. In the Assay, the principal peak in the chromatogram obtained with solution (2) has the sameretention time as that in the chromatogram obtained with solution (1).

B. To 1 ml add a 0.25% w/v solution of iron(III) chloride hexahydrate dropwise until a green colour isproduced. On the gradual addition of sodium hydrogen carbonate solution, the solution changes first toblue and then to red.

C. To 10 ml add 2 ml of a 10% w/v solution of disodium hydrogen orthophosphate and sufficientiodinated potassium iodide solution to produce a brown colour and remove excess iodine by adding 0.1Msodium thiosulphate dropwise. A red colour is produced.


Noradrenaline Carry out the method for liquid chromatography, Appendix III D, using the followingsolutions. Solution (1) contains 0.0018% w/v of noradrenaline acid tartrate in the mobile phase. Forsolution (2) use the injection. Solution (3) contains 0.0018% w/v of adrenaline acid tartrate BPCRSand 0.0018% w/v of noradrenaline acid tartrate in the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as themobile phase with a flow rate of 2 ml per minute a solution containing 4.0 g of tetramethylammoniumhydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodium edetate in a mixture of950 ml of water and 50 ml of methanol and adjusting the pH to 3.5 with 1M sodium hydroxide and (c) adetection wavelength of 205 nm.


In the chromatogram obtained with solution (2) the area of any peak corresponding tonoradrenaline is not greater than the area of the principal peak in the chromatogram obtained withsolution (1).

Assay Carry out the method for liquid chromatography, Appendix III D, using the following solutions.Solution (1) contains 0.02% w/v of adrenaline acid tartrate BPCRS in the mobile phase. For solution(2) dilute 1 volume of the injection to 10 volumes with the mobile phase. Solution (3) contains0.02% w/v of adrenaline acid tartrate BPCRS and 0.02% w/v of noradrenaline acid tartrate in the mobilephase.

The chromatographic procedure may be carried out using (a) a stainless steel column (10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as the mobile phasewith a flow rate of 2 ml per minute a solution prepared by adding 4.0 g of tetramethylammoniumhydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodium edetate to a mixture of950 ml of water and 50 ml of methanol and adjusting the pH of the mixture to 3.5 with 1M sodiumhydroxide and (c) a detection wavelength of 205 nm.


Calculate the content of C9H13NO3 in the injection using the declared content of C9H13NO3 inadrenaline acid tartrate BPCRS.

Storage Adrenaline Injection should be protected from light.Labelling The label states (1) Adrenaline Injection and Epinephrine Injection.

The quantity of active ingredient is stated in terms of the equivalent amount of adrenaline(epinephrine).

Adrenaline Injection contains the equivalent of adrenaline (epinephrine), 1 in 1000 (1 mg in 1 ml).

46-17

Dilute Adrenaline Injection 1 in 10,000 /Dilute Epinephrine Injection 1 in10,000For the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Dilute Adrenaline Injection 1 in 10,000 is a sterile, isotonic solution containing either0.018% w/v of Adrenaline Acid Tartrate or 0.01% w/v of adrenaline hydrochloride, prepared by theinteraction of Adrenaline and Hydrochloric Acid, in Water for Injections.



Characteristics A colourless or almost colourless solution.

Identification A. In the Assay, the chromatogram obtained with solution (1) shows a peak with thesame retention time as the principal peak in the chromatogram obtained with solution (2).

B. To 10 ml add 2 ml of a 10% w/v solution of disodium hydrogen orthophosphate and sufficientiodinated potassium iodide solution to produce a brown colour and remove excess iodine by adding 0.1Msodium thiosulphate dropwise. A red or pink colour is produced.


Noradrenaline Carry out the method for liquid chromatography, Appendix III D, using the followingsolutions. Solution (1) contains 0.00018% w/v of noradrenaline acid tartrate in the mobile phase. Forsolution (2) use the injection. Solution (3) contains 0.00018% w/v of adrenaline acid tartrate BPCRSand 0.00018% w/v of noradrenaline acid tartrate in the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as themobile phase with a flow rate of 2 ml per minute a solution containing 4.0 g of tetramethylammoniumhydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodium edetate in a mixture of950 ml of water and 50 ml of methanol and adjusting the pH to 3.5 with 1M sodium hydroxide and (c) adetection wavelength of 205 nm.

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution factorbetween the two principal peaks is at least 2.0.

In the chromatogram obtained with solution (2) the area of any peak corresponding tonoradrenaline is not greater than the area of the principal peak in the chromatogram obtained withsolution (1) (1%, calculated with respect to the content of adrenaline).

Assay Carry out the method for liquid chromatography, Appendix III D, using the following solutions.Solution (1) contains 0.02% w/v of adrenaline acid tartrate BPCRS in the mobile phase. Solution (2)is the injection. Solution (3) contains 0.02% w/v of adrenaline acid tartrate BPCRS and 0.02% w/v ofnoradrenaline acid tartrate in the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column (10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as the mobile phasewith a flow rate of 2 ml per minute a solution prepared by adding 4.0 g of tetramethylammoniumhydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodium edetate to a mixture of950 ml of water and 50 ml of methanol and adjusting the pH of the mixture to 3.5 with 1M sodiumhydroxide and (c) a detection wavelength of 205 nm.

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution factorbetween the two principal peaks is at least 2.0.

Calculate the content of C9H13NO3 in the injection using the declared content of C9H13NO3 inadrenaline acid tartrate BPCRS.

Storage Dilute Adrenaline Injection 1 in 10,000 should be protected from light.

Labelling The label states Dilute Adrenaline Injection (1 in 10,000) and Dilute EpinephrineInjection 1 in 10,000.


Dilute Adrenaline Injection contains the equivalent of adrenaline (epinephrine), 1 in 10,000 (100 gin 1 ml).

46-18

Adrenaline Solution / Epinephrine SolutionAdrenaline Tartrate SolutionEpinephrine Tartrate Solution


Definition Adrenaline Solution is an isotonic cutaneous solution containing 0.18% w/v of AdrenalineAcid Tartrate with a suitable combination of an antioxidant and an antimicrobial preservative inPurified Water.

The solution complies with the requirements stated under Liquids for Cutaneous Application and with thefollowing requirements.


Characteristics A clear, colourless solution.

IdentificationA. In the Assay, the principal peak in the chromatogram obtained with solution (2) has the sameretention time as that in the chromatogram obtained with solution (1).

B. To 1 ml add a 0.25% w/v solution of iron(III) chloride hexahydrate dropwise until a green colour isproduced. On the gradual addition of sodium hydrogen carbonate solution, the solution changes first toblue and then to red.

C. To 10 ml add 2 ml of a 10% w/v solution of disodium hydrogen orthophosphate and sufficientiodinated potassium iodide solution to produce a brown colour and remove excess iodine by adding 0.1Msodium thiosulphate dropwise. A red colour is produced.


Noradrenaline Complies with the test described under Adrenaline Eye Drops but using the prepara-tion being examined as solution (2).

Assay Carry out the method for liquid chromatography, Appendix III D, using the following solutions.Solution (1) contains 0.02% w/v of adrenaline acid tartrate BPCRS in the mobile phase. For solution(2) dilute 1 volume of the preparation being examined to 10 volumes with the mobile phase. Solution(3) contains 0.02% w/v of adrenaline acid tartrate BPCRS and 0.02% w/v of noradrenaline acid tartratein the mobile phase.

The chromatographic procedure may be carried out using (a) a stainless steel column(10 cm 4.6 mm) packed with stationary phase C (5 m) (Nucleosil C18 is suitable), (b) as themobile phase with a flow rate of 2 ml per minute a solution prepared by adding 4.0 g of tetra-methylammonium hydrogen sulphate, 1.1 g of sodium heptanesulphonate and 2 ml of 0.1M disodiumedetate to a mixture of 950 ml of water and 50 ml of methanol and adjusting the pH of the mixture to3.5 with 1M sodium hydroxide and (c) a detection wavelength of 205 nm.


Calculate the content of C9H13NO3 in the preparation being examined using the declared contentof C9H13NO3 in adrenaline acid tartrate BPCRS.

Storage Adrenaline Solution should be kept in a well-filled, well-closed, glass container suitable forparenteral preparations, Appendix XIX B, and should be protected from light.

Labelling The label states (1) Adrenaline Solution and Epinephrine Solution; (2) the date afterwhich the solution is not intended to be used; (3) the conditions under which it should be stored.


The label indicates the pharmaceutical form as cutaneous solution.

Adrenaline Solution contains the equivalent of adrenaline (epinpehrine), 1 in 1000 (1 mg in 1 ml).

When a solution of adrenaline hydrochloride is prescribed or demanded, a solution complying withthe requirements of this monograph may be dispensed or supplied.

46-19

Paediatric Alimemazine Oral Solution/ Paediatric Trimeprazine OralSolutionFor the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Paediatric Alimemazine Oral Solution is a solution containing 0.15% w/v of AlimemazineTartrate in a suitable flavoured vehicle.

The oral solution complies with the requirements stated under Oral Liquids and with the following require-ments.

Content of alimemazine tartrate, C36H44N4S2, C4H6O6 0.135 to 0.165% w/v.

Identification Dilute 50 ml with 175 ml of water and add 7 ml of 1M sodium hydroxide. Extract with100 ml of ether, wash the ether layer with 15 ml of water and dry over anhydrous sodium sulphate(solution A).A. Evaporate 30 ml of solution A to dryness and dissolve the residue in 100 ml of a mixture of 1volume of 5M ammonia and 99 volumes of methanol. Dilute 4 ml of the resulting solution to 100 mlwith the same solvent mixture. The light absorption of the resulting solution, Appendix II B, in therange 230 to 350 nm exhibits a maximum at 255 nm and a less well-defined maximum at 301 nm.

B. Evaporate 30 ml of solution A to dryness and dissolve the residue in 0.2 ml of chloroform. Theinfrared absorption spectrum of the resulting solution, Appendix II A, is concordant with the referencespectrum of alimemazine (RS 005).

C. Evaporate 30 ml of solution A to dryness and add 0.05 ml of a mixture of 0.1 ml of formaldehydesolution and 1 ml of sulphuric acid to the residue. A purple colour is produced.

Related substances Complies with the test for related substances in phenothiazines, Appendix III A,using mobile phase A and the following freshly prepared solutions. For solution (1) dilute 15 ml withan equal volume of water, add 2 ml of 1M sodium hydroxide and extract with two 15-ml quantities ofchloroform. Dry the chloroform extracts with anhydrous sodium sulphate, filter and evaporate the filtrateto dryness. Dissolve the residue as completely as possible in 1 ml of a mixture of 95 volumes ofmethanol and 5 volumes of diethylamine. For solution (2) dilute 1 volume of solution (1) to 50volumes with the same solvent mixture.

Assay Carry out the following procedure protected from light. To a weighed quantity containing15 mg of Alimemazine Tartrate add 25 ml of water and 5 ml of a 5% w/v solution of sodiumhydroxide. Extract the mixture with two 50-ml quantities of chloroform, shaking vigorously for 1minute each time, evaporate the combined extracts to dryness at about 30 at a pressure of 2 kPa anddissolve the residue in sufficient 0.1M hydrochloric acid to produce 50 ml (solution B). Dilute 10 ml ofsolution B to 50 ml with water (solution C). To a further 10 ml of solution B add 5 ml of peroxyaceticacid solution, allow to stand for 10 minutes and add sufficient water to produce 50 ml (solution D).Measure the absorbance of solution D at the maximum at 342 nm, Appendix II B, using solution C inthe reference cell and measure the absorbance of solution C at the same wavelength using water in thereference cell. Repeat the procedure using a 0.03% w/v solution of alimemazine tartrate BPCRS in0.1M hydrochloric acid in place of solution B and beginning at the words Dilute 10 ml of ....Determine the weight per ml of the oral solution, Appendix V G, and calculate the content ofC36H44N4S2,C4H6O6, weight in volume, using the declared content of C36H44N4S2,C4H6O6 inalimemazine tartrate BPCRS. The result is not valid if the absorbance of solution C is more than 0.10.

Storage Paediatric Alimemazine Oral Solution should be protected from light.

Labelling The label states Paediatric Alimemazine Oral Solution and Paediatric Trimeprazine OralSolution.

Paediatric Alimemazine Oral Solution contains in 5 ml 7.5 mg of Alimemazine Tartrate(Trimeprazine Tartrate).

46-20

Strong Paediatric Alimemazine Oral Solution / Strong PaediatricTrimeprazine Oral SolutionFor the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Strong Paediatric Alimemazine Oral Solution is a solution containing 0.6% w/v ofAlimemazine Tartrate in a suitable flavoured vehicle.

The oral solution complies with the requirements stated under Oral Liquids and with the following require-ments.

Content of alimemazine tartrate, C36H44N4S2, C4H6O6 0.54 to 0.66% w/v.

Identification Complies with the tests stated under Paediatric Alimemazine Oral Solution but using15 ml of the oral solution to prepare solution A.

Related substances Complies with the test for related substances in phenothiazines, Appendix III A,using mobile phase A and the following freshly prepared solutions. For solution (1) dilute 5 ml with15 ml of water, add 2 ml of 1M sodium hydroxide and extract with two 15-ml quantities of chloroform.Dry the chloroform extracts with anhydrous sodium sulphate, filter and evaporate the filtrate todryness. Dissolve the residue as completely as possible in 1 ml of a mixture of 95 volumes of methanoland 5 volumes of diethylamine. For solution (2) dilute 1 volume of solution (1) to 50 volumes withthe same solvent mixture.

Assay Carry out the Assay described under Paediatric Alimemazine Oral Solution but using assolution B a solution prepared in the following manner. To a weighed quantity containing 30 mg ofAlimemazine Tartrate add 25 ml of water and 5 ml of a 5% w/v solution of sodium hydroxide. Extractthe mixture with two 50-ml quantities of chloroform, shaking vigorously for 1 minute each time,evaporate the combined extracts to dryness at about 30 at a pressure of 2 kPa and dissolve theresidue in sufficient 0.1M hydrochloric acid to produce 100 ml.

Storage Strong Paediatric Alimemazine Oral Solution should be protected from light.

Labelling The label states Strong Paediatric Alimemazine Oral Solution and Strong PaediatricTrimeprazine Oral Solution.

Strong Paediatric Alimemazine Oral Solution contains in 5 ml 30 mg of Alimemazine Tartrate(Trimeprazine Tartrate).

46-21

Alimemazine Tablets /Trimeprazine TabletsFor the purposes of product labelling in the United Kingdom, the pair of names given above shall be usedtogether (see Supplementary Chapter II A, Changes in title).

Definition Alimemazine Tablets contain Alimemazine Tartrate.


Content of alimemazine tartrate, C36H44N4S2, C4H6O6 92.5 to 107.5% of the stated amount.

IdentificationA. To a quantity of the powdered tablets containing 40 mg of Alimemazine Tartrate add 10 ml ofwater and 2 ml of 1M sodium hydroxide, shake and extract with 15 ml of ether. Wash the ether layerwith 5 ml of water, dry with anhydrous sodium sulphate and evaporate the ether to dryness. Dissolvethe residue in 0.4 ml of chloroform. The infrared absorption spectrum of the resulting solution, AppendixII A, is concordant with the reference spectrum of alimemazine (RS 005).

B. To a quantity of the powdered tablets containing 1 mg of Alimemazine Tartrate add 1 ml of amixture of equal volumes of formaldehyde solution and sulphuric acid. A purple colour is produced.

Related substances Comply with the test for related substances in phenothiazines, Appendix III A,using mobile phase A and applying separately to the plate 20 l of each of the following freshlyprepared solutions. For solution (1) extract a quantity of the powdered tablets containing 0.1 g ofAlimemazine Tartrate with 10 ml of a mixture of 95 volumes of methanol and 5 volumes of diethyl-amine and filter. For solution (2) dilute 1 volume of solution (1) to 200 volumes with the samesolvent mixture.

Assay Carry out the following procedure protected from light. Add 150 ml of 0.1M hydrochloric acidto 10 tablets, shake for 10 minutes, mix with the aid of ultrasound for 1 minute, dilute with 0.1Mhydrochloric acid to produce a solution containing 0.050% w/v of Alimemazine Tartrate and filter(solution A). Dilute 10 ml of solution A to 100 ml with water (solution B). To a further 10 ml ofsolution A add 2 ml of peroxyacetic acid solution, mix, allow to stand for 5 minutes and add sufficientwater to produce 100 ml (solution C). Measure the absorbance of solution C at the maximum at342 nm, Appendix II B, using solution B in the reference cell and measure the absorbance of solutionB at the same wavelength using water in the reference cell. Repeat the procedure using a 0.05% w/vsolution of alimemazine tartrate BPCRS in 0.1M hydrochloric acid in place of solution A, beginning atthe words Dilute 10 ml of solution A ... and calculate the content of C36H44N4S2,C4H6O using thedeclared content of C36H44N4S2,C4H6O in alimemazine tartrate BPCRS. The test is not valid if theabsorbance of solution B is more than 0.10.

Labelling The label states Alimemazine Tablets and Trimeprazine Tablets.

46-22

Allopurinol TabletsDefinition Allopurinol Tablets contain Allopurinol.


Content of allopurinol, C5H4N4O 92.5 to 107.5% of the stated amount.

IdentificationA. The light absorption, Appendix II B, in the range 230 to 350 nm of the solution obtained in theAssay exhibits a maximum only at 250 nm.

B. Shake a quantity of the powdered tablets containing 0.1 g of Allopurinol with 5 ml of 1.25Msodium hydroxide and add 3 ml of phosphomolybdotungstic reagent and 5 ml of a 20% w/v solution ofsodium carbonate. A greyish blue colour is produced.

Related substances Carry out the method for thin-layer chromatography, Appendix III A, using silicagel GF254 as the coating substance and a mixture of 60 volumes of butan-2-one, 20 volumes of 13.5Mammonia and 20 volumes of 2-methoxyethanol as the mobile phase. Apply separately to the plate 10 lof each of the following solutions. For solution (1) shake a quantity of the powdered tablets contain-ing 0.25 g of Allopurinol with 10 ml of a 10% v/v solution of diethylamine and filter. Solution (2)contains 0.0050% w/v of allopurinol impurity A EPCRS in 13.5M ammonia. After removal of the plate,allow it to dry in a current of air and examine under ultraviolet light (254 nm). Any secondary spot inthe chromatogram obtained with solution (1) is not more intense than the spot in the chromatogramobtained with solution (2).

Assay Weigh and powder 20 tablets. Shake a quantity of the powder containing 0.1 g of Allopurinolwith 20 ml of 0.05M sodium hydroxide for 20 minutes, add 80 ml of 0.1M hydrochloric acid, shake for10 minutes, add sufficient 0.1M hydrochloric acid to produce 250 ml, filter and dilute 10 ml of thefiltrate to 250 ml with 0.1M hydrochloric acid. Measure the absorbance of the resulting solution at themaximum at 250 nm, Appendix II B, using 0.1M hydrochloric acid in the reference cell. Calculate thecontent of C5H4N4O taking 563 as the value of A(1%, 1 cm) at the maximum at 250 nm.

46-23

Almond Oil Ear DropsDefinition Almond Oil Ear Drops are Virgin Almond Oil in a suitable container.

The ear drops comply with the requirements stated under Ear Preparations and with the following require-ments.

Identification Carry out the test for the identification of fixed oils by thin-layer chromatography,Appendix X N. The chromatogram obtained from the oil being examined shows spots correspondingto those in the typical chromatogram for almond oil.

Acid value Not more than 2.0, Appendix X B. Use 5 g dissolved in 50 ml of the prescribed mixtureof solvents.

Peroxide value Not more than 10, Appendix X F.

Relative density 0.911 to 0.920, Appendix V G.

Unsaponifiable matter Not more than 0.7% w/w, Appendix X H, Method II. Use 5 g.

Apricot-kernel oil and peach-kernel oil Shake 2 ml for 5 minutes with a mixture of 1 ml offuming nitric acid and 1 ml of water and allow to separate. No pink or brown colour develops in eitherlayer.

Foreign fixed oils Carry out the test for foreign oils by gas chromatography, Appendix X N. The fatty-acid fraction of the oil has the following composition.Saturated fatty acids of chain length less than C16 Not more than 0.1%.Palmitic acid 4.0 to 9.0%.Palmitoleic acid (equivalent chain length on polyethylene glycol adipate, 16.3) Not more than 0.6%.Margaric acid Not more than 0.2%.Stearic acid Not more than 3.0%.Oleic acid (equivalent chain length on polyethylene glycol adipate, 18.3) 62.0 to 86.0%.Linoleic acid (equivalent chain length on polyethylene glycol adipate, 18.9) 20.0 to 30.0%.Linolenic acid (equivalent chain length on polyethylene glycol adipate, 19.7) Not more than 0.4%.Arachidic acid Not more than 0.1%.Gadoleic acid (equivalent chain length on polyethylene glycol adipate, 20.3) Not more than 0.1%.Behenic acid Not more than 0.1%.Erucic acid (equivalent chain length on polyethylene glycol adipate, 22.3) Not more than 0.1%.

Sterols Carry out the test for sterols in fatty oils, Appendix X N. The sterol fraction of the oil has thefollowing composition.Cholesterol Not more than 0.7%.Campesterol Not more than 4.0%.Stigmasterol Not more than 3.0%.b-Sitosterol 73.0% to 87.0%.D5-Avenasterol At least 10.0%.D7-Avenasterol Not more than 3.0%.D7-Stigmastenol Not more than 3.0 per cent.Fucosterol Not more than 2.0 per cent.Brassicasterol Not more than 0.3%.

Sesame oil Shake 10 ml with 5 ml of a mixture of 0.5 volume of a 0.35% v/v solution offurfuraldehyde in acetic anhydride and 4.5 volumes of acetic anhydride for 1 minute, filter through afilter paper impregnated with acetic anhydride and add 0.2 ml of sulphuric acid. No bluish green colourdevelops.

Storage Almond Oil Ear Drops should be kept in a well-filled, well-closed container and protectedfrom light.

46-24

Standardised Aloes Dry Extract

Standardised Aloes Dry Extract complies with the requirements of the 3rd edition of the European Pharmaco-poeia [0259]. These requirements are reproduced after the heading Definition below.

Ph Eur ___________________________________________________________________________________________________________

DEFINITION

Standardised aloes dry extract is prepared from Barbados aloes or Cape aloes, or a mixture of thetwo, by treatment with boiling water. It is adjusted, if necessary, to contain not less than 19.0 percent and not more than 21.0 per cent of hydroxyanthracene derivatives, expressed as barbaloin(C21H22O9; Mr 418.4) and calculated with reference to the dried extract.

CHARACTERS

A brown or yellowish-brown powder, sparingly soluble in boiling water.

IDENTIFICATION

A. Examine by thin-layer chromatography (2.2.27), using silica gel G R as the coating substance.

Test solution. To 0.25 g of the preparation to be examined add 20 ml of methanol R and heat to boil-ing in a water-bath. Shake for a few minutes and decant the solution. Store at about 4C and usewithin 24 h.

Reference solution. Dissolve 25 mg of barbaloin R in methanol R and dilute to 10 ml with the samesolvent.

Apply separately to the plate as bands 20 mm by not more than 3 mm 10 l of each solution.Develop over a path of 10 cm using a mixture of 13 volumes of water R, 17 volumes of methanol Rand 100 volumes of ethyl acetate R. Allow the plate to dry in air, spray with a 100 g/l solution ofpotassium hydroxide R in methanol R and examine in ultraviolet light at 365 nm. The chromatogramobtained with the test solution shows in the central part a zone of yellow fluorescence (barbaloin)similar in position to the zone corresponding to barbaloin in the chromatogram obtained with thereference solution and in the lower part there is a zone of light blue fluorescence (aloesine). In thelower part of the chromatogram obtained with the test solution two zones of yellow fluorescence(aloinosides A and B) (Cape aloes) and one zone of violet fluorescence just below the zone corres-ponding to barbaloin (Barbados aloes) may be present.

B. Shake 1 g of the preparation to be examined with 100 ml of boiling water R. Cool, add 1 g oftalc R and filter. To 10 ml of the filtrate add 0.25 g of disodium tetraborate R and heat to dissolve.Pour 2 ml of the solution into 20 ml of water R. A yellowish-green fluorescence appears which isparticularly marked in ultraviolet light at 365 nm.

TESTS

Loss on drying Not more than 4.0 per cent m/m, determined as prescribed in the monograph onExtracts (765) (Dry extracts).

Total ash (2.4.16). Not more than 2.0 per cent.

ASSAY

Carry out the assay protected from bright light.

Introduce 0.400 g into a 250 ml conical flask. Moisten with 2 ml of methanol R, add 5 ml of water Rwarmed to about 60C, mix, add a further 75 ml of water R at about 60C and shake for 30 min.Cool, filter into a volumetric flask, rinse the conical flask and filter with 20 ml of water R, add therinsings to the volumetric flask and dilute to 1000.0 ml with water R. Transfer 10.0 ml of this solu-tion to a 100 ml round-bottomed flask containing 1 ml of a 600 g/l solution of ferric chloride R and6 ml of hydrochloric acid R. Heat in a water-bath under a reflux condenser for 4 h, with the water levelabove that of the liquid in the flask. Allow to cool, transfer the solution to a separating funnel, rinsethe flask successively with 4 ml of water R, 4 ml of 1M sodium hydroxide and 4 ml of water R, and addthe rinsings to the separating funnel. Shake the contents of the separating funnel with three quanti-ties, each of 20 ml, of ether R. Wash the combined ether layers with two quantities, each of 10 ml, ofwater R. Discard the washings and dilute the organic phase to 100.0 ml with ether R. Evaporate20.0 ml carefully to dryness on a water-bath and dissolve the residue in 10.0 ml of a 5 g/l solution ofmagnesium acetate R in methanol R. Measure the absorbance (2.2.25) at 512 nm using methanol R asthe compensation liquid.

Calculate the percentage content of hydroxyanthracene derivatives, as barbaloin, from theexpression:

46-25

m.A 619

i.e. taking the specific absorbance of barbaloin to be 255.A=absorbance at 512 nm,m =mass of the substance to be examined in grams.

STORAGE

See the monograph on Extracts (765) (Dry extracts).

LABELLING

See the monograph on Extracts (765) (Dry extracts).__________________________________________________________________________________________________________ Ph Eur

46-26

Aloxiprin TabletsDefinition Aloxiprin Tablets contain Aloxiprin.


Content of total salicylates 92.5 to 107.5% of the stated amount, calculated as O-acetylsalicylicacid, C9H8O4.

Identification To 0.5 g of the powdered tablets add 5 ml of hydrochloric acid, boil, cool and filter.Wash the residue with 20 ml of water and combine the filtrate and washings. The resulting solutionyields the reaction characteristic of aluminium salts and, after neutralisation with 1M sodium hydroxide,yields reaction A characteristic of salicylates, Appendix VI.

Disintegration Maximum time, 5 minutes, Appendix XII A.

Free salicylates To a quantity of the powdered tablets containing the equivalent of 0.6 g of totalsalicylates add 50 ml of dry ether and shake for 30 minutes. Filter rapidly through fluted filter paperand wash the paper with several portions of dry ether. To the combined filtrate and washings add10 ml of 1M sodium hydroxide, swirl to mix and evaporate the ether on a water bath. Cool, adjust thepH to between 2.40 and 2.50 with 1M hydrochloric acid and dilute to 100 ml with water. To 20 ml ofthe resulting solution add 4 ml of iron(III) chloride solution and dilute to 50 ml with acetate buffer pH2.45. Allow to stand for 30 minutes, filter, if necessary, through a pair of fluted filter papers andmeasure the absorbance of the solution at the maximum at 530 nm, Appendix II B, using in thereference cell a solution prepared by diluting 4 ml of iron(III) chloride solution to 50 ml with acetatebuffer pH 2.45. The absorbance is not more than that obtained using 5 ml of a 0.036% w/v solutionof salicylic acid diluted to 20 ml with water in place of the solution being examined and beginning atthe words add 4 ml of iron(III) chloride solution ... (1.5%, calculated with reference to the content oftotal salicylates).

Combined salicylate Not more than 15.0%, calculated as salicylic acid, C7H6O3, with reference tothe content of total salicylates when determined by the following method. To a quantity of the finelypowdered tablets containing the equivalent of 0.15 g of total salicylates add 40 ml of a 0.5% w/vsolution of sodium fluoride in 0.1M hydrochloric acid and shake for 5 minutes. Allow the mixture tostand for 10 minutes, shaking at frequent intervals, extract with six 20-ml quantities of chloroform,filter the combined extracts through anhydrous sodium sulphate, wash with 30 ml of chloroform anddilute to 200 ml with chloroform. Dilute 20 ml of the solution to 100 ml with chloroform and measurethe absorbance of the resulting solution at the maximum at 308 nm, Appendix II B. Calculate thecontent of C7H6O3 taking 293 as the value of A(1%, 1 cm) at the maximum at 308 nm.

Assay Weigh and finely powder 20 tablets. To a quantity of the powder containing the equivalent of0.3 g of total salicylates add 50 ml of 1M sodium hydroxide and boil gently for 15 minutes withoccasional swirling. Cool, adjust the pH of the mixture to between 2.40 and 2.50 with 1M hydrochloricacid and dilute to 500 ml with water. Filter a portion of the suspension; to 5 ml of the filtrate add35 ml of acetate buffer pH 2.45 and 4 ml of iron(III) chloride solution and dilute to 50 ml with water.Allow to stand for 30 minutes and measure the absorbance of the resulting solution at the maximumat 530 nm, Appendix II B, using in the reference cell a solution prepared by diluting 4 ml of iron(III)chloride solution to 50 ml with acetate buffer pH 2.45. Calculate the content of total salicylates asO-acetylsalicylic acid, C9H8O4, from the absorbance obtained by repeating the procedure using 4 mlof a 0.05% w/v solution of salicylic acid in place of the solution being examined and beginning at thewords add 35 ml of acetate buffer pH 2.45 .... Each g of salicylic acid is equivalent to 1.305 g ofC9H8O4.

Labelling The quantity of active ingredient is stated both as the amount of Aloxiprin and in terms ofthe equivalent amount of total salicylates calculated as O-acetylsalicylic acid, C9H8O4.

46-27

Compound Aluminium PasteBaltimore Paste

Definition Compound Aluminium Paste contains 20% w/w of Aluminium Powder and 40% w/w ofZinc Oxide in a suitable hydrophobic liquid basis.

Extemporaneous preparation The following formula and directions apply.

Aluminium Powder 200 gZinc Oxide 400 gLiquid Paraffin 400 g

Mix the Aluminium Powder and the Zinc Oxide with the Liquid Paraffin until smooth.

The paste complies with the requirements stated under Topical Semi-solid Preparations and with the followingrequirements.

Content of aluminium, Al 15.8 to 20.0% w/w.

Content of zinc oxide, ZnO 37.0 to 42.0% w/w.

IdentificationA. To 5 ml of solution A prepared in the Assay for aluminium add 2 ml of ammonia buffer pH 10.9,centrifuge and reserve the supernatant liquid. Dissolve the residue in the minimum quantity of 2Mhydrochloric acid and add 0.25 ml of ammonium acetate solution and 0.25 ml of a 0.1% w/v solution ofmordant blue 3. An intense purple colour is produced.

B. Add 2 ml of sodium sulphide solution to the supernatant liquid reserved in test A, centrifuge,dissolve the sediment in the minimum volume of 1M sulphuric acid and add 0.05 ml of a 0.1% w/vsolution of copper(II) sulphate and 2 ml of ammonium mercurithiocyanate reagent. A violet precipitate isproduced.

AssayFor aluminium Disperse 1 g in a mixture of 20 ml of hydrochloric acid and 20 ml of water with theaid of gentle heat, filter, wash the filter with water, cool the combined filtrate and washings and diluteto 100 ml with water (solution A). Neutralise 10 ml of solution A to congo red paper with 5M sodiumhydroxide, add 50 ml of 0.05M disodium edetate VS, heat on a water bath for 30 minutes, cool, add 3 gof hexamine and titrate the excess of disodium edetate with 0.05M lead nitrate VS, using xylenol orangesolution as indicator, to a purplish red colour. Add 1 g of sodium fluoride to the resulting solution, heaton a water bath for 15 minutes, cool and continue the titration to a purplish red colour. The volumeof 0.05M lead nitrate VS used in the second titration represents the amount of disodium edetateliberated from the complex. Each ml of 0.05M disodium edetate VS is equivalent to 1.349 mg of Al.

For zinc oxide The difference between the volume of 0.05M disodium edetate VS added in the Assayfor aluminium and the total volume of 0.05M lead nitrate VS used represents the amount of zincpresent. Each ml of 0.05M disodium edetate VS is equivalent to 4.068 mg of ZnO.

46-28

Aluminium Acetate Ear DropsDefinition

Aluminium Sulphate 225 gCalcium Carbonate 100 gTartaric Acid 45 gAcetic Acid (33 per cent) 250 mlPurified Water 750 ml

Extemporaneous preparation The following directions apply.

Dissolve the Aluminium Sulphate in 600 ml of the Purified Water, add the Acetic Acid and then theCalcium Carbonate mixed with the remainder of the Purified Water and allow to stand for not lessthan 24 hours in a cool place, stirring occasionally. Filter, add the Tartaric Acid to the filtrate andmix.

The ear drops comply with the requirements stated under Ear Preparations and with the following require-ments.

Content of aluminium, Al 1.7 to 1.9% w/v.

Characteristics A clear liquid.

Weight per ml 1.06 to 1.08 g, Appendix V G.

Assay Dilute 10 ml to 100 ml with water. To 10 ml of the resulting solution add 40 ml of 0.05Mdisodium edetate VS, 90 ml of water and 0.15 ml of methyl red solution. Neutralise by the dropwiseaddition of 1M sodium hydroxide and warm on a water bath for 30 minutes. Cool, add 1 ml of 2M nitricacid and 5 g of hexamine and titrate with 0.05M lead nitrate VS using 0.5 ml of xylenol orange solutionas indicator. Each ml of 0.05M disodium edetate VS is equivalent to 1.349 mg of Al.

Storage Aluminium Acetate Ear Drops should be kept in a well-filled container and stored at atemperature not exceeding 25.

When aluminium acetate solution or Burows Solution is prescibed or demanded a solutioncomplyimg with the requirements of this monograph shall be dispensed or supplied.

46-29

Aluminium Chloride SolutionDefinition Aluminium Chloride Solution is a cutaneous solution. It contains Aluminium ChlorideHexahydrate in a suitable ethanolic vehicle.

Production In making Aluminium Chloride Solution, Industrial Methylated Spirits may be usedprovided that the law and the statutory regulations governing the use of Industrial Methylated Spiritsare observed.

The solution complies with the requirements stated under Liquids for Cutaneous Application and with thefollowing requirements.

Content of aluminium chloride hexahydrate, AlCl3,6H2O 95.0 to 105.0% of the stated amount.

Identification Dilute the solution with water to produce a solution containing 2% w/v of AluminiumChloride Hexahydrate. The solution yields reaction A characteristic of aluminium salts and reaction Acharacteristic of chlorides, Appendix VI.

Iron Dilute the solution being examined with water to produce a solution containing 10.0% w/v ofAluminium Chloride Hexahydrate. 10 ml of this solution complies with the limit test for iron,Appendix VII (10 ppm, determined with respect to the content of aluminium chloride hexahydrate).

Ethanol Not less than 70.0% v/v, Appendix VIII F.

Assay To a weighed quantity containing about 0.4 g of Aluminium Chloride Hexahydrate add 25 mlof water and carry out the complexometric titration of aluminium, Appendix VIII D. Each ml of 0.1Mdisodium edetate VS is equivalent to 24.14 mg of AlCl3,6H2O.

If the declared content is in terms of weight in volume, determine the weight per ml of the solution,Appendix V G, and hence calculate the content of AlCl3,6H2O, weight in volume.

Storage Aluminium Chloride Solution should be stored at a temperature not exceeding 25. Thecontainer should be kept upright.

Labelling The label states (1) the date after which the solution is not intended to be used; (2) theconditions under which it should be stored; (3) that the solution is flammable.

The label states indicates the pharmaceutical form as cutaneous solution.

46-30

Aluminium Hydroxide Oral SuspensionDefinition Aluminium Hydroxide Oral Suspension is an aqueous suspension of hydrated aluminiumoxide together with varying quantities of basic aluminium carbonate. It contains the equivalent of 4%w/w of aluminium oxide and has a peppermint flavour.

The oral suspension complies with the requirements stated under Oral Liquids and with the following require-ments.

Content of aluminium oxide, Al2O3 The equivalent of 3.5 to 4.4% w/w.

Characteristics A white suspension from which small amounts of clear liquid may separate onstanding. It may exhibit thixotropic properties.

Identification A solution in 2M hydrochloric acid yields the reaction characteristic of aluminium salts,Appendix VI.

Alkalinity pH, when diluted with an equal volume of carbon dioxide-free water, not more than 7.5,Appendix V L.

Neutralising capacity Disperse 5 g in 100 ml of water, heat to 37, add 100 ml of 0.1M hydrochloricacid VS previously heated to 37 and stir continuously, maintaining the temperature at 37. The pHof the solution, at 37, after 10, 15 and 20 minutes, is not less than 1.8, 2.3 and 3.0 respectively andat no time during this period is it more than 4.0. Add 10 ml of 0.5M hydrochloric acid VS previouslyheated to 37, stir continuously for 1 hour maintaining the temperature at 37 and titrate the solutionwith 0.1M sodium hydroxide VS to pH 3.5. Not more than 50 ml of 0.1M sodium hydroxide VS isrequired.

Ammonium salts To 25 g in an ammonia-distillation apparatus add 25 ml of 5M sodium hydroxideand 250 ml of water, distil about 100 ml, collecting the distillate in 25 ml of 0.1M hydrochloric acidVS, and titrate the excess of acid with 0.1M sodium hydroxide VS using methyl red solution as indicator.Not less than 20.0 ml of 0.1M sodium hydroxide VS is required.

Arsenic Dissolve 2.0 g in 18 ml of brominated hydrochloric acid and 32 ml of water. 25 ml of theresulting solution complies with the limit test for arsenic, Appendix VII (1 ppm).

Heavy metals Dissolve 2.0 g in 20 ml of 1M hydrochloric acid and 10 ml of water, add 0.5 ml of nitricacid and boil for about 30 seconds. Cool, add 2 g of ammonium chloride and 2 g of ammoniumthiocyanate and extract with two 10-ml quantities of a mixture of equal volumes of isoamyl alcohol andether. To the aqueous layer add 2 g of citric acid and dilute to 40 ml with water. 12 ml of the resultingsolution complies with limit test A for heavy metals, Appendix VII. Use lead standard solution (1 ppmPb) to prepare the standard (20 ppm).

Chloride Dissolve 0.30 g in 2 ml of 2M nitric acid, boil, cool, dilute to 250 ml with water and filter.15 ml of the filtrate complies with the limit test for chlorides, Appendix VII (0.3%).

Sulphate Dissolve 0.50 g in 5 ml of 2M hydrochloric acid, boil, cool, dilute to 200 ml with water andfilter. 12.5 ml of the filtrate, diluted to 15 ml with 2M hydrochloric acid, complies with the limit test forsulphates, Appendix VII (0.5%).

Microbial contamination Carry out a quantitative evaluation for Enterobacteria and certain otherGram-negative bacteria, Appendix XVI B1. 0.01 ml of the preparation gives a negative result, Table I(most probable number of bacteria per gram fewer than 102).

Assay Dissolve 5 g in 3 ml of hydrochloric acid by warming on a water bath, cool to below 20 anddilute to 100 ml with water. To 20 ml of this solution add 40 ml of 0.05M disodium edetate VS, 80 mlof water and 0.15 ml of methyl red solution and neutralise by the dropwise addition of 1M sodiumhydroxide. Heat on a water bath for 30 minutes, add 3 g of hexamine and titrate with 0.05M lead nitrateVS using 0.5 ml of xylenol orange solution as indicator. Each ml of 0.05M disodium edetate VS is equiva-lent to 2.549 mg of Al2O3.

Storage Aluminium Hydroxide Oral Suspension should be kept at a temperature not exceeding 30.It should not be allowed to freeze.

46-31

Aluminium Hydroxide TabletsDefinition Aluminium Hydroxide Tablets contain, in each, 500 mg of Dried Aluminium Hydroxidein a suitable basis with a peppermint flavour.


Content of aluminium oxide, Al2O3 Not less than the equivalent of 0.225 g.

Identification The powdered tablets yield the reaction characteristic of aluminium salts, AppendixVI, and have the odour of peppermint.

Disintegration The requirement for Disintegration does not apply to Aluminium HydroxideTablets.

Neutralising capacity Pass a sufficient quantity of the powder prepared for use in the Assaythrough a sieve with a nominal mesh aperture of 150 m. Mix a quantity of the powder containing0.5 g of Dried Aluminium Hydroxide with a small quantity of water to give a smooth paste and slowlyadd further quantities of water to a total volume of 100 ml. Warm to 37, add 100 ml of 0.1M

Documents

BP_04 - 2001